Calidi Biotherapeutics, Inc. Common Stock (CLDI)
Frequently Asked Questions About Calidi Biotherapeutics, Inc. Common Stock (CLDI)
How can I stay updated on Calidi Biotherapeutics news?
To stay updated on Calidi Biotherapeutics news, investors and interested parties can follow the company’s official website, subscribe to news releases, and follow their social media channels. Additionally, financial news outlets provide regular updates on publicly traded companies.
How does Calidi Biotherapeutics engage with the scientific community?
Calidi Biotherapeutics actively engages with the scientific community through partnerships with research institutions, hosting and participating in scientific conferences, and contributing to peer-reviewed publications. This collaborative approach fosters innovation and advancements in cancer therapeutics.
How does Calidi Biotherapeutics fund its operations?
Calidi Biotherapeutics funds its operations through a combination of public investments, private funding rounds, grants, and potential collaborations with pharmaceutical companies and academic institutions. Funding is crucial for supporting ongoing research, development efforts, and clinical trials.
Is Calidi Biotherapeutics publicly traded?
Yes, Calidi Biotherapeutics, Inc. is publicly traded on the New York Stock Exchange under the ticker symbol CLDI. This allows investors to buy and sell shares in the company, supporting its financial growth and ability to fund ongoing research and development efforts.
What are the future plans for Calidi Biotherapeutics?
Calidi Biotherapeutics plans to continue advancing its clinical pipeline, expanding research collaborations, and potentially exploring new oncology indications. The company aims to leverage its technology to deliver innovative treatments that improve the quality of life for cancer patients.
What are the recent milestones for Calidi Biotherapeutics?
Recent milestones for Calidi Biotherapeutics include successful completion of preclinical studies, initiation of clinical trials for its lead product candidates, and securing partnerships with academic institutions for collaborative research. These achievements contribute to the company's aim of bringing new therapies to oncology.
What are the risks associated with investing in Calidi Biotherapeutics?
Investing in Calidi Biotherapeutics carries several risks, including the inherent uncertainty of clinical trials, regulatory hurdles, potential delays in product development, and competition from other biotech firms. Investors should conduct thorough due diligence and consider these risks before investing.
What does Calidi Biotherapeutics, Inc. do?
Calidi Biotherapeutics, Inc. is a biotechnology company focused on developing innovative therapies using its proprietary platform that combines oncolytic virus technology with cancer immunotherapy. The company's goal is to target and destroy cancer cells while simultaneously stimulating the immune system to recognize and attack tumors.
What is an oncolytic virus?
An oncolytic virus is a type of virus that selectively infects and kills cancer cells. Unlike regular viruses that aim to propagate and spread within a host, oncolytic viruses have been modified to enhance their ability to target tumor cells, thereby destroying malignant tissue without significantly harming normal cells.
What is Calidi's differentiation in the biotech industry?
Calidi Biotherapeutics differentiates itself in the biotech industry through its unique oncolytic virus platform, which allows for the direct targeting of tumors while also amplifying the body's immune response. This dual-action mechanism aims to improve therapeutic efficacy compared to traditional cancer treatments.
What is the company’s approach to immunotherapy?
Calidi Biotherapeutics employs a combined modality approach to immunotherapy by using oncolytic viruses in conjunction with immune checkpoint inhibitors. This method aims to enhance the overall response of the immune system to cancer by both directly attacking tumor cells and removing the inhibitory signals that prevent immune activation.
What is the company’s pipeline of clinical trials?
Calidi Biotherapeutics has a robust pipeline of clinical trials aimed at evaluating the safety and efficacy of its oncolytic virus therapies in various cancers. The company continuously monitors and updates its progress in these trials as it seeks to bring new, effective cancer treatments to market.
What is the mission of Calidi Biotherapeutics?
The mission of Calidi Biotherapeutics is to improve cancer treatment outcomes by leveraging innovative biotherapeutic approaches. The company aims to harness the body’s immune system to combat tumors more effectively and provide safer, more targeted treatment options for patients with various types of cancer.
What is the regulatory pathway for Calidi's therapies?
Calidi Biotherapeutics follows the regulatory pathways established by the U.S. Food and Drug Administration (FDA) for developing and approving new therapies. This includes navigating preclinical studies, Investigational New Drug (IND) applications, clinical trials, and ultimately seeking approval for market launch.
What partnerships does Calidi Biotherapeutics have?
Calidi Biotherapeutics has established partnerships with various academic institutions and research organizations to enhance its research capabilities and clinical trial execution. These collaborations help in advancing therapeutic development and may lead to innovative synergistic approaches in cancer treatment.
What types of cancer is Calidi Biotherapeutics targeting?
Calidi Biotherapeutics targets several types of cancer, including but not limited to melanoma, pancreatic cancer, and various solid tumors. The company’s research focuses on cancers for which existing therapies have limited effectiveness, aiming to provide new avenues for patient treatment.
Where is Calidi Biotherapeutics, Inc. headquartered?
Calidi Biotherapeutics, Inc. is headquartered in San Diego, California. This region is well-known for its robust life sciences and biotechnology sector, which enables the company to attract talent and collaborate with leading research institutions and hospitals.
Who are the key executives at Calidi Biotherapeutics?
Calidi Biotherapeutics is led by a team of experienced professionals in the fields of biotechnology and pharmaceuticals, including Chief Executive Officer (CEO) and Chief Scientific Officer (CSO) whose backgrounds encompass extensive experience in drug development, clinical trials, and business management within the biotech sector.
What is the current price of Calidi Biotherapeutics, Inc. Common Stock?
The current price of Calidi Biotherapeutics, Inc. Common Stock is 0.2402
When was Calidi Biotherapeutics, Inc. Common Stock last traded?
The last trade of Calidi Biotherapeutics, Inc. Common Stock was at 8:00 pm EDT on July 7th, 2025
What is the market capitalization of Calidi Biotherapeutics, Inc. Common Stock?
The market capitalization of Calidi Biotherapeutics, Inc. Common Stock is 7.64M
How many shares of Calidi Biotherapeutics, Inc. Common Stock are outstanding?
Calidi Biotherapeutics, Inc. Common Stock has 31.79M shares outstanding.